Switchover Trial From Imiglucerase to Plant Cell Expressed Recombinant Human Glucocerebrosidase

Inclusion Criteria: * Males and females, 2 years or older * Confirmed diagnosis of Gaucher disease by the enzymatic activity assay * Stable Gaucher disease * Treatment with imiglucerase (Cerezyme®) for at least 2 years and on a stable maintenance regimen (dose and regimen unchanged, except for situation of drug shortage) for at least the last six months * Able to provide written informed consent Exclusion Criteria: * Currently taking another experimental drug for any condition * History of allergy to carrots * History of allergy to beta lactam antibiotics * Previous infusion reaction suspected to be allergic in nature to Cerezyme® or Ceredase® or receiving premedication to prevent infusion reactions * Presence of HIV and/or HBsAg and/or hepatitis C infection * Presence of unresolved anemia due to iron, folic acid or vitamin B12 deficiency * Presence of any significant comorbidity that could confound the interpretation of the clinical response to taliglucerase alfa * Presence of any medical, emotional, behavioral or psychological condition that in the judgment of the Investigator would interfere with the patient's compliance with the requirements of the study